|
|
 | | | |
- close
- close
- close
- close
Aeterna Zentaris Inc (AEZ) |
QUOTE AND NEWS
PR Newswire
May 16
Comment
QUEBEC CITY, May 16, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that it has received a notice from The NASDAQ Stock Market indicating that the Company's minimum bid price has fallen
PR Newswire
May 9
Comment
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 9, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today reported financial and operating results as at and for the first quarter ended
PR Newswire
May 7
Comment
NEW YORK, May 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the Company and Aeterna Zentaris Inc. have executed a License Termination and Technology Transfer Agreement, whereby the KRX-0401 (perifosine)
PR Newswire
May 7
Comment
Aeterna Zentaris to continue ongoing Phase 3 trial in multiple myeloma QUEBEC CITY, May 7, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it and Keryx Biopharmaceuticals, Inc. ("Keryx")
PR Newswire
May 3
Comment
QUÉBEC CITY, May 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior VP and Chief Medical Officer, Paul Blake MD, will be presenting a corporate overview at the 11(th) Annual JMP
PR Newswire
May 1
Comment
QUEBEC CITY, May 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2012 financial and operating results before market open on Wednesday, May 9, 2012. The Company will host a
PR Newswire
Apr 3
Comment
AEZS-136 shows synergy and efficacy in human tumor cells QUÉBEC CITY, April 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on its novel orally active anticancer PI3K/Erk 1/2
PR Newswire
Apr 2
Comment
QUÉBEC CITY, April 2, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Phase 3 "X-PECT" (Xeloda® + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating
PR Newswire
Mar 29
Comment
QUÉBEC CITY, March 29, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel, PhD, will be presenting a corporate overview at the 11(th) Annual Needham
PR Newswire
Mar 27
Comment
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 27, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrine
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
